In this work, we identified a set of eleven AD cohorts that contained the CSF biomarkers recommended for applying the ATN framework (i.e., Aβl-42, phosphorylated tau 181 (pTau), and total tau (tTau)) (1). Here, MAPT is linked to Alzheimer disease.